SM
BIIB icon

SG3 Management’s Biogen BIIB Stock Holding History

SG3 Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,500
Closed -$4.02M – 35
2022
Q4 		$4.02M Sell
14,500
-4,500
-24% -$1.27M 0.58% 40
2022
Q3 		$5.07M Sell
19,000
-29,500
-61% -$6.27M 0.68% 35
2022
Q2 		$9.89M Buy
48,500
+29,500
+155% +$6.03M 1.16% 15
2022
Q1 		$4M Sell
19,000
-72,000
-79% -$15.7M 0.11% 170
2021
Q4 		$21.8M Buy
91,000
+20,000
+28% +$5.14M 0.44% 36
2021
Q3 		$20.1M Buy
71,000
+5,000
+8% +$1.64M 0.61% 22
2021
Q2 		$22.9M Sell
66,000
-3,000
-4% -$909K 0.81% 18
2021
Q1 		$19.3M Sell
69,000
-46,200
-40% -$12.5M 0.48% 30
2020
Q4 		$28.2M Buy
115,200
+58,200
+102% +$15M 0.54% 25
2020
Q3 		$16.2M Buy
+57,000
New +$15.9M 0.6% 32
2017
Q1 		– Sell
-5,000
Closed -$1.31M – 229
2016
Q4 		$1.31M Buy
+5,000
New +$1.48M 0.21% 83

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SG3 Management's BIIB Position: Q2 2022 in Review

SG3 Management sold out of Biogen (BIIB) in Q2 2022, closing a stake of 15,000 shares — an estimated $3.07M sold.

SG3 Management first reported a position in BIIB in Q4 2020 and held it in 5 quarters. The position peaked at $8.77M in Q1 2021. 928 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

  • SG3 Management reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 15,000 Biogen shares in Q2 2022, an estimated $3.07M.
  • SG3 Management first reported a position in Biogen in Q4 2020 and held it in 5 quarters.
  • SG3 Management's Biogen position peaked at $8.77M in Q1 2021.
  • 928 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.